ROR1 and neoplasm: The anticancer activity of zilovertamab vedotin is primarily due to binding of the ADC to ROR1-expressing tumor cells, internalization of the ADC–ROR1 complex with trafficking to tumor cell lysosomes, and release of MMAE via lysosomal proteolytic cleavage (8, 9).